Alliance Funded Drug Delivery System Shows Promise in Recent Clinical Study

BIND Biosciences, a company established by Alliance researchers from MIT and Harvard Medical School, published their first results of a clinical study indicating that their targeted nanotherapeutic (BIND-014) is well tolerated and capable of shrinking patient tumors. Read more

Quantum Dots Provide Quantitative Profile of Pancreatic Cancer Biomarkers on Single Cells

Nanoparticle-Delivered RNA Interference Drug Stops Head and Neck Cancer Growth

Using Radio Waves to Bake Tumors

Carbon Nanotubes Kill Breast Cancer Stem Cells

DNA Nanorobot Targets Therapeutic Responses

Nanoparticles Enhance Combination Chemotherapy and Radiation Therapy

Successful Human Tests for First Wirelessly Controlled Drug-Delivery Chip

Enter your email below to receive news and updates:

NCI Initiates Public-Private Industry Partnership

NCI announces the launch of Translation of Nanotechnology in Cancer (TONIC), a public-private partnership to accelerate the translation and development of nanotechnology solutions for the early detection, diagnosis, and treatment of cancer.

TONIC will work in parallel to the Alliance, enabling collaboration across government, academia, industry, and non-profits to translate safe and effective diagnosis and treatment options to the clinic.

Learn more about TONIC and how to participate.

Nanotechnology allows researchers to study cancer in its earliest stages of progression, enabling early detection and development of novel therapies to target the disease. Learn more about nanotechnology's impact on cancer

Learn more about potential uses for nanotechnology for diagnosing and treating cancer. Listen to the podcast series